Loxo Sells Bayer Rights To Rare Cancer Drug For More Than $1 Billion

Bayer will pay $400 million -- and up to $1.15 million more in milestones tied to regulatory approvals and sales -- for commercial rights to a rare cancer drug being developed by Loxo Oncology, a small Stamford, Conn.-based biotechnology firm.